Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.41 CAD 0.71% Market Closed
Market Cap: 140.3m CAD

Cardiol Therapeutics Inc
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cardiol Therapeutics Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Stock-Based Compensation
CA$10.8m
CAGR 3-Years
15%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Stock-Based Compensation
$175m
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
3%
Canopy Growth Corp
TSX:WEED
Stock-Based Compensation
CA$7.1m
CAGR 3-Years
-40%
CAGR 5-Years
-48%
CAGR 10-Years
22%
Sundial Growers Inc
NASDAQ:SNDL
Stock-Based Compensation
CA$19.8m
CAGR 3-Years
29%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Stock-Based Compensation
$8m
CAGR 3-Years
-15%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Stock-Based Compensation
CA$4.7m
CAGR 3-Years
39%
CAGR 5-Years
20%
CAGR 10-Years
2%
No Stocks Found

Cardiol Therapeutics Inc
Glance View

Market Cap
140.3m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
HIDDEN
Show

See Also

What is Cardiol Therapeutics Inc's Stock-Based Compensation?
Stock-Based Compensation
10.8m CAD

Based on the financial report for Sep 30, 2025, Cardiol Therapeutics Inc's Stock-Based Compensation amounts to 10.8m CAD.

What is Cardiol Therapeutics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
29%

Over the last year, the Stock-Based Compensation growth was -11%. The average annual Stock-Based Compensation growth rates for Cardiol Therapeutics Inc have been 15% over the past three years , 29% over the past five years .

Back to Top